ReviewNature reviews. Clinical oncology2025
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.
Review in Nature reviews. Clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07674498 (Prediction of Response Related to IMmune Age T Cell Fitness in Elderly Patients With Relapsed and Refractory Multiple Myeloma), which is not on this map. Cited by 98 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prediction of Response Related to IMmune Age T Cell Fitness in Elderly Patients With Relapsed and Refractory Multiple Myeloma
Who cites it
98 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).American journal of hematology · 2026Pooled it
- International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Guideline
- Anti-CD38-based quadruplet versus triplet induction regimens in transplant-ineligible newly diagnosed multiple myeloma: a systematic review and meta-analysis.International journal of hematology · 2026Pooled it
- Risk for second primary malignancies in patients with multiple myeloma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- First-Line treatment for transplant-ineligible newly diagnosed multiple myeloma: a Bayesian network meta-analysis of efficacy, safety, and high-risk subgroups.Frontiers in immunology · 2026Pooled it
- Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.Frontiers in oncology · 2025Pooled it
- Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers.British journal of haematology · 2026Trial
- Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.Nature medicine · 2026Trial
- Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial.British journal of haematology · 2026Trial
- MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM.British journal of haematology · 2026Trial
- Trial
- Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma.Blood cancer journal · 2025Trial
- Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma.The New England journal of medicine · 2025Trial
- Transition from inpatient to outpatient step-up dosing of bispecific antibodies in multiple myeloma: real-world insights.Blood advances · 2026Article
- Patient preferences for treatment‑free intervals in multiple myeloma: mixed‑methods insights on monitoring trade‑offs and supportive care improvements.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- [Imaging in monoclonal plasma cell disorders : Multiple myeloma, smouldering multiple myeloma and MGUS].Radiologie (Heidelberg, Germany) · 2026Review
- An analysis of different reconstruction techniques for the radius: a finite element analysis.Biomechanics and modeling in mechanobiology · 2026Article
- Article
- Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third-Line or Later Relapsed/Refractory Multiple Myeloma.American journal of hematology · 2026Article
- REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials.Haematologica · 2026Observational
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the publication in 2021 of the European Hematology Association (EHA) Clinical Practice Guidelines for the treatment of patients with smouldering multiple myeloma (SMM) and multiple myeloma (MM), developed in collaboration with the European Society for Medical Oncology, a novel international staging system (R2-ISS) has been developed, several prognostic factors are entering clinical practice (such as minimal residual disease, circulating plasma cells and monoclonal protein assessed by mass spectrometry) and, at the time of writing, 14 novel regimens have been approved by the EMA and/or the FDA for the treatment of patients with MM. A multidisciplinary group of experts from the EHA and European Myeloma Network, based in various institutions mostly located in Europe, have updated the previous guidelines and produced algorithms for everyday clinical practice that incorporate levels of evidence and grades of recommendation based on the aforementioned new data. In these Evidence-Based Guidelines, we provide key treatment recommendations for both patients with newly diagnosed MM and those with relapsed and/or refractory MM, including guidance for the use of established drugs as well as contemporary immunotherapies. Novel approaches for the management of patients with SMM focus on those who might require early intervention. Finally, we provide recommendations for myeloma-related complications and adverse events, such as bone disease, renal impairment and infections, as well as for those associated with T cell-mobilizing therapies, such as cytokine-release syndrome and immune effector cell-associated neurotoxicity syndrome.
Indexed as
Identifiers
40624367What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.